002788.SZ(002788.SZ)

$11.76—

Chart

002788.SZ(002788.SZ)

SHZ

$11.76—

Chart Studio

002788.SZ(002788.SZ)

002788.SZ

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

8/15/26

LUYAN PHARMA CO.,LTD. (002788.SZ)

Saturday

7:32 PM

Thesis: Recent strategic partnerships and anticipated product approvals are likely to enhance revenue growth prospects, shifting investor sentiment positively.

Revenue Outlook

Metric	FY2024	FY2025
Revenue	$20.5B	$21.2B
Rev. Growth	+3.2%	+3.8%
EPS	$0.89	$0.72
EPS Growth	-5.3%	-19.1%
P/E	13.2×	16.3×

What’s Driving the Stock

1Luyan Pharma's recent partnership with a Southeast Asian distributor could potentially increase revenue by 15% over the next year.
2The company is expected to file for approval of a new traditional Chinese medicine product by Q3 2026, which could significantly boost sales.
3Recent cost-cutting measures have improved the gross margin from 7.1% to an expected 9.5% in the next quarter.
4Growing demand for traditional Chinese medicine in global markets
5Increased focus on biotechnology and personalized medicine
6Regulatory approvals for new drug applications
7Changes in healthcare policies affecting pharmaceutical pricing
8Market expansion efforts in Southeast Asia

FY2025 Snapshot

Revenue: $21.2B
Rev. Growth: +3.8%
Gross Margin: 7.1%
Op. Margin: 1.8%
Net Margin: 1.3%
Net Income: $281M
NI Growth: -18.7%
EPS: $0.72
1Y Return: +42.5%

002788.SZ Chart

My Notes

"Management highlighted, 'Our strategic initiatives are positioning us for significant growth in the coming quarters.'"
Moat: Luyan Pharma's competitive advantage is bolstered by its unique product offerings in traditional Chinese medicine and established…
value - Investors may be attracted due to the low price-to-sales ratio of 0.2x, indicating potential undervaluation.
Interest rates impact Luyan Pharma's financing costs, particularly given its high debt-to-equity ratio of 2.13…
Watch on earnings: Regulatory approval timelines for new drugs, R&D spending as a percentage of revenue, Market share in traditional Chinese medicine.

One Sentence Summary:

Luyan Pharma Co.,Ltd.: the setup is constructive — luyan pharma's recent partnership with a southeast asian distributor could potentially increase revenue by 15% over the next year.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2024

FY2025

P/E

13.2×

16.3×

What’s Driving the Stock

1Luyan Pharma's recent partnership with a Southeast Asian distributor could potentially increase revenue by 15% over the next year.

2The company is expected to file for approval of a new traditional Chinese medicine product by Q3 2026, which could significantly boost sales.

3Recent cost-cutting measures have improved the gross margin from 7.1% to an expected 9.5% in the next quarter.

4Growing demand for traditional Chinese medicine in global markets

5Increased focus on biotechnology and personalized medicine

6Regulatory approvals for new drug applications

7Changes in healthcare policies affecting pharmaceutical pricing

8Market expansion efforts in Southeast Asia

My Notes

"Management highlighted, 'Our strategic initiatives are positioning us for significant growth in the coming quarters.'"

Moat: Luyan Pharma's competitive advantage is bolstered by its unique product offerings in traditional Chinese medicine and established…

value - Investors may be attracted due to the low price-to-sales ratio of 0.2x, indicating potential undervaluation.

Interest rates impact Luyan Pharma's financing costs, particularly given its high debt-to-equity ratio of 2.13…

Watch on earnings: Regulatory approval timelines for new drugs, R&D spending as a percentage of revenue, Market share in traditional Chinese medicine.